Warner-Lambert Company

Dennis M Downing

Jonathan L Wright

Lawrence D Wise

Stephen J Johnson

David Juergen Wustrow

Juan C Jaen

Bradley W Caprathe

William J Smith, Iii

Jeremy John Edmunds

Shelly Ann Glase

Kent A Berryman

Danette Andrea Dudley

Stephen Taras Rapundalo

Lakshmi Sourirajan Narasimhan

This invention discloses benzoxazinone and benzothiazinone compounds which display inhibitory effects on serine proteases such as factor Xa, thrombin, and/or factor VIIa. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing disease states in mammals characterized by abnornal thrombosis.

Benzoxazinoes/benzothiazinones as serine protease inhibitors

Sulfonylquinolines are described, as well as methods for the preparation and pharmaceutical composition of same, which are useful as central nervous system agents and are particularly useful as antiobesity agents and for the treatment of hypertension.

Sulfonylquinolines as central nervous system and cardiovascular agents

Benzimidazoles and imidazopyridines are described, as well as methods for the preparation and pharmaceutical composition of same, which are useful as central nervous system agents and are particularly useful as antipsychotic agents and for the treatment of disorders which respond to dopaminergic blockade including psychotis depression, substance abuse, and compulsive disorders.

Benzimidazoles and imidazopyridines as central nervous system agents

Dimeric benzimidazoles are described, as well as methods for the preparation and pharmaceutical composition of same, which are useful as central nervous system agents and are particularly useful as antipsychotic agents and for the treatment of disorders which respond to dopaminergic blockade including psychotic depression, substance abuse, and compulsive disorders.

Dimeric benzimidazoles as central nervous system agents

1,3-Substituted cycloalkenes and cycloalkanes are described, as well as methods for the preparation and pharmaceutical composition of same, which are useful as central nervous system agents and are particularly useful as dopaminergic, antipsychotic, and antihypertensive agents as well as for treating hyperprolactinaemia-related conditions and central nervous system disorders.

1,3-substituted cycloalkenes and cycloalkanes as central nervous system

Growing community of inventors

Ann Arbor, MI, United States of America

Dennis M Downing